查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1984182

下一代生物製造市場：2026-2032年全球市場預測（依產品類型、技術、製程階段、業務規模、細胞株、製程模式及最終用戶分類）

Next-Generation Biomanufacturing Market by Product Type, Technology, Process Stage, Operation Scale, Cell Line, Process Mode, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計下一代生物製造市場在 2025 年的價值為 4.6622 億美元，在 2026 年成長到 5.9443 億美元，到 2032 年達到 26.2487 億美元，複合年成長率為 28.00%。

主要市場統計數據
基準年 2025 4.6622億美元
預計年份：2026年 5.9443億美元
預測年份 2032 2,624,870,000 美元
複合年成長率 (%) 28.00%

本書權威地介紹了下一代生物製造技術，重點在於先進生物製藥開發、模組化生產架構、人才策略和全球供應鏈韌性。

在生物製劑的快速發展、靈活的生產技術以及後疫情時代對韌性供應鏈的需求推動下，下一代生物製造正成為未來十年最重要的產業變革之一。本文概述指出，該領域不僅是現有製造能力的演進，更是治療藥物發現、生產和交付方式的系統性變革。在整個開發平臺中，研發人員正致力於開發日益複雜的治療方法，包括細胞和基因療法、重組蛋白、單株抗體和新型疫苗平台，這推動了對能夠同時支援小批量、個人化生產和可擴展商業供應的生產架構的需求。

突破性的技術創新、監管變革和商業性變化如何重新定義全球生物製造能力、製程架構、資本配置和策略投資。

生物製造領域的格局正因技術創新、法規演變和商業策略的交會而重塑，並受到多項變革性變化的影響。首先，科技融合正在加速。連續生物製程和先進分析技術正與一次性硬體和模組化設施設計相結合，建構出兼具柔軟性和高度自動化的系統。這種融合縮短了技術轉移週期，減少了停留時間，並提高了品質特性的可預測性。隨著製程的成熟，所有這些因素共同降低了操作的複雜性。

評估 2025 年美國關稅措施對整個生物製造生態系統的原物料採購、契約製造經濟、跨境供應鏈、資本配置和近岸外包決策的累積影響。

美國2025年實施的關稅措施對整個生物製造生態系統產生了複雜且累積的影響，其影響遠不止於直接的成本上漲。初期，關稅將推高進口原料、一次性組件和專用設備的到貨成本，促使採購團隊重新評估其供應商組合和合約條款。隨著時間的推移，這些增加的投入成本可能會改變採購週期，從而可能促使企業進行批量採購和簽訂長期供應契約，以對沖關稅波動風險。因此，籌資策略正從現貨採購轉向能夠提供價格穩定和技術合作的策略夥伴關係。

關鍵的細分洞察揭示了產品類型、底層技術、各個製程階段、不同的最終用戶、業務規模、細胞株選擇和製程模式的細微差異如何決定產能投資和商業化策略。

一套精細的細分框架清楚地闡明了在產品類型、技術、製程階段、最終用戶、業務規模、細胞株和製程模式等方面，能力投資和策略重點在哪些領域能夠產生最大影響。就產品類型而言，細胞和基因療法需要獨特的生產模式，包括CAR-T療法、細胞療法和基因編輯療法，這些療法對小批量、患者特異性的生產物流高度敏感。另一方面，酶的應用涵蓋診斷和工業領域，在這些領域，通量和成本效益至關重要。單株抗體可分為自體免疫、感染疾病和腫瘤治療應用，每種應用對效力和純度的要求各不相同。重組蛋白，包括細胞激素、生長因子和激素，通常需要嚴格控制上游和下游工作流程。疫苗涵蓋廣泛的平台，包括活病毒疫苗、mRNA疫苗、次單位疫苗和病毒載體疫苗，每種疫苗都有其獨特的低溫運輸和填充/表面處理工程。

美洲、歐洲、中東和非洲以及亞太地區的區域趨勢和戰略意義，對生物製造領導者的生產能力位置、監管協調、人才流動和跨境合作產生影響。

區域趨勢是企業在決定生產能力位置、供應鏈結構和監管路徑時進行策略決策的核心。在美洲，先進的臨床生態系統、強勁的投資者興趣和密集的供應商網路正在推動利基產品製造的發展，以實現快速商業化和個人化療法。然而，供應鏈摩擦和政策不確定性仍然可能導致選擇性近岸外包和更嚴格的供應商篩選。在歐洲、中東和非洲，監管協調和強力的公私合營關係正在為大批量生技藥品和疫苗生產創造極具吸引力的地點。然而，細微的區域監管差異需要製定針對特定區域的申請策略，並延長產品上市時間。

這提供了企業級的洞察，重點介紹了製藥開發公司、契約製造製造商、技術提供商和系統整合商如何重組其產品組合、建立策略聯盟以及最佳化其製造地以抓住機會。

生物製造價值鏈上的主要企業正透過產能擴張、策略夥伴關係和有針對性地採用新技術來適應不斷變化的市場環境。契約製造正日益提供從細胞庫和分析開發到商業規模填充和包裝等一系列整合服務，以獲取更大價值並加快客戶的產品上市速度。技術供應商則專注於模組化、一次性產品和數位化平台，以實現遠端監控和預測性維護，從而降低營運風險並支援多地點協作。製藥研發公司則透過保留對細胞株開發和製程表徵等關鍵流程的策略控制權，同時將常規的規模化生產和大規模生產外包給專業合作夥伴，來打造差異化優勢。

為行業領導者提供可操作的策略建議，以加速採用先進的生物程序，確保有韌性的供應鏈網路，使商業模式適應不斷變化的法規，並優先考慮可擴展的投資以獲得長期競爭優勢。

在技​​術和政策快速變化的背景下，行業領導者應採取切實可行且優先級明確的行動，以保持競爭優勢。首先，應加快採用模組化和一次性資產，用於早期和靈活的商業化生產，以縮短部署時間並減輕驗證負擔。這種方法使企業能夠在有限的資本框架內試點創新製程模式，例如灌注培養和連續層析法，然後在產品經濟效益證明大規模的固定投資合理時，選擇性地擴大生產規模。其次，應實現供應商多元化，並加強策略採購協議，以減輕關稅相關的成本波動，並最大限度地降低單一供應商失效的風險。同時，應制定緊急時應對計畫，包括本地製造合作夥伴和檢驗的替代供應商。

這種高度透明的研究方法詳細介紹了綜合的一手和二手研究、專家訪談、數據檢驗、檢驗過程、細分映射和可重複的評估調查方法，以產生可靠的市場洞察。

本分析的調查方法採用綜合方法，結合一手訪談、二手文獻整合和嚴謹的檢驗，確保研究結果的穩健性和可重複性。一手研究包括對研發、製造、採購和監管部門高階主管的結構化訪談，以及與技術供應商、系統整合商和契約製造的深入交流。這些交流揭示了技術轉移和規模化生產中的實際限制、投資重點以及挑戰實例。二手研究涵蓋了同行評審文獻、公開的監管指導文件和技術白皮書，以闡明發展趨勢並檢驗技術論點。

對於希望在下一代生物製造領域佔據主導的相關人員，這提供了簡潔的策略結論，整合了關鍵點、必要的風險緩解措施、投資重點和前瞻性考慮因素。

總之，下一代生物製藥代表著一個策略轉折點，技術創新、供應鏈策略和監管調整在此交匯融合，重塑產業的經濟結構和競爭力。連續生物製程、模組化設施、一次性系統和數位分析技術的成熟，為更快、更可靠地生產複雜生物製藥鋪平了道路，但要實現這些優勢，需要對能力建設和夥伴關係關係進行審慎的投資。因此，領導者必須根據每種製程的具體需求調整資本配置，優先考慮供應商在面對地緣政治因素和關稅波動時的韌性，並組成能夠管理自動化、數據驅動型營運的跨職能團隊。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 下一代生物製造市場：依產品類型分類

  • 細胞和基因治療
    • CAR-T療法
    • 細胞療法
    • 基因編輯療法
  • 酵素
    • 診斷酶
    • 工業酵素
  • 單株抗體
    • 自體免疫
    • 感染疾病
    • 腫瘤學
  • 重組蛋白
    • 細胞激素
    • 生長因子
    • 荷爾蒙
  • 疫苗
    • 減毒活病毒疫苗
    • 藥效疫苗
    • 次單位疫苗
    • 病毒載體疫苗

第9章：下一代生物製造市場：依技術分類

  • 無細胞系統
    • 無細胞表現試劑盒
    • 無細胞合成平台
  • 連續生物程序
    • 連續層析法
    • 在線連續監測系統
    • 灌注系統
  • 模組化設施
    • 預製模組
    • 滑座式系統
  • 免洗系統
    • 免洗袋子
    • 免洗生物反應器
    • 一次性軟管和接頭

第10章 依製程階段分類的下一代生物製造市場

  • 下游工藝
    • 層析法
    • 過濾
    • 純化
  • 配方
    • 填充和精加工
    • 冷凍乾燥
    • 包裝
  • 上游工程
    • 生物反應器運行
    • 細胞培養
    • 培養基製備

第11章 按營運規模分類的下一代生物製造市場

  • 臨床量表
  • 商業規模
  • 中試規模

第12章細胞株系視野下的下一代生物製造市場

  • Cho 細胞
    • Cho-DG44
    • Cho-K1
  • 大腸桿菌
    • Bl21
    • K12
  • 酵母菌
    • 畢赤酵母
    • 釀酒酵母

第13章 按製程模式分類的下一代生物製造市場

  • 批次
  • 連續型
  • 聯邦批次
  • 灌注

第14章 下一代生物製造市場：依最終用戶分類

  • 學術和研究機構
  • 生技公司
  • 契約製造組織
  • 製藥公司

第15章 下一代生物製造市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第16章 下一代生物製造市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第17章 下一代生物製造市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第18章：美國下一代生物製造市場

第19章：中國的下一代生物製造市場

第20章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Agilent Technologies, Inc.
  • Amyris, Inc.
  • Applikon Biotechnology BV
  • bbi-biotech GmbH
  • Biofluidica, Inc.
  • Codexis, Inc.
  • Danaher Corporation
  • Eppendorf AG
  • ESCO Group
  • Eurofins Scientific SE
  • Evolva Holding SA
  • Evonik Industries AG
  • GEA Group AG
  • GENEWIZ, Inc. by Azenta Life Sciences
  • Genomatica, Inc.
  • Ginkgo Bioworks Holdings, Inc.
  • Hamilton Company
  • Illumina, Inc.
  • Koninklijke DSM NV
  • LanzaTech, Inc.
  • Macrogen Inc.
  • Merck KGaA
  • Novozymes A/S
  • Oxford Nanopore Technologies plc
  • PBS Biotech, Inc.
  • PerkinElmer Inc.
  • QIAGEN NV
  • Sartorius AG
  • Shanghai Bailun Biotechnology Co., Ltd.
  • Solaris Biotechnology Srl by DONALDSON ITALIA SRL
  • Takara Bio Inc.
  • Thermo Fisher Scientific Inc.
  • ZETA GmbH
  • Zymergen Inc.
Product Code: MRR-5C6F41F5AFEF

The Next-Generation Biomanufacturing Market was valued at USD 466.22 million in 2025 and is projected to grow to USD 594.43 million in 2026, with a CAGR of 28.00%, reaching USD 2,624.87 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 466.22 million
Estimated Year [2026] USD 594.43 million
Forecast Year [2032] USD 2,624.87 million
CAGR (%) 28.00%

An authoritative introduction positioning next-generation biomanufacturing at the intersection of advanced biologics development, modular production architectures, workforce talent strategies, and global supply resilience

Next-generation biomanufacturing is emerging as one of the most consequential industrial transformations of the coming decade, propelled by rapid advances in biologics, flexible production technologies, and a post-pandemic imperative for resilient supply chains. This introduction frames the sector not merely as an evolution of existing manufacturing capabilities but as a systemic shift in how therapeutics are discovered, produced, and delivered. Across development pipelines, developers are pursuing increasingly complex modalities including cell and gene therapies, recombinant proteins, monoclonal antibodies, and novel vaccine platforms, driving demand for production architectures that can support small-batch personalization and scalable commercial supply concurrently.

Moreover, new manufacturing paradigms-such as modular facilities, single-use systems, continuous bioprocessing, and cell-free technologies-are enabling faster time-to-clinic, reduced capital intensity for initial capacity, and improved responsiveness to demand variability. Consequently, operational priorities now include rapid technology transfer, enhanced process analytics for inline monitoring, and workforce upskilling to manage programmable, highly automated operations. As stakeholders evaluate strategic options, this report positions the industry's trajectory in terms of capability buildout, competitive dynamics among developers and contract manufacturers, and the policy environments influencing cross-border supply. In doing so, it provides a structured foundation for leaders seeking to balance innovation speed, manufacturing reliability, and regulatory compliance.

How transformative technological innovations, regulatory recalibrations, and commercial shifts are collectively redefining biomanufacturing capacity, process architectures, capital allocation, and strategic investments worldwide

The landscape of biomanufacturing is being reshaped by several transformative shifts that intersect technological innovation, regulatory evolution, and commercial strategy. First, technological convergence is accelerating: continuous bioprocessing and advanced analytics are merging with single-use hardware and modular facility designs to produce systems that are both flexible and highly automated. This convergence shortens technology transfer cycles, reduces hold times, and enables more predictable quality attributes, which collectively lower operational complexity as processes mature.

Second, regulatory pathways are adapting to accommodate novel modalities and decentralized production models. In turn, regulators are placing greater emphasis on real-time release testing, risk-based validation approaches, and harmonization efforts that reduce duplication across markets. As a result, manufacturers that proactively invest in robust process characterization and digital quality architectures are increasingly positioned to gain regulatory latitude and accelerate time-to-patient.

Third, commercial models are evolving in response to demand fragmentation and premium pricing dynamics for personalized therapies. Contract development and manufacturing organizations will therefore take on greater responsibility for end-to-end program delivery, including integrated analytics, cell banking, and cold-chain logistics orchestration. Finally, strategic capital allocation is shifting toward platforms that offer rapid scalability-prefabricated modules and skid-mounted systems-enabling companies to respond to therapeutic breakthroughs and regional demand shifts with lower up-front risk. Together, these shifts are not isolated; they interact to create a new operational logic where speed, quality, and adaptability determine competitive advantage.

Assessing the cumulative effects of United States tariff actions in 2025 on raw material sourcing, contract manufacturing economics, cross-border supply chains, capital deployment, and nearshoring decisions across biomanufacturing ecosystems

United States tariff actions in 2025 have imposed a complex, cumulative set of effects across the biomanufacturing ecosystem, with implications that extend beyond immediate cost inflation. Initially, tariffs increase the landed cost of imported raw materials, single-use components, and specialized instrumentation, prompting sourcing teams to reassess supplier portfolios and contractual terms. Over time, those higher input costs alter procurement rhythms and may incentivize bulk purchasing or long-term supply agreements to hedge against tariff volatility. As a result, purchasing strategies are shifting from spot buys toward strategic relationships that offer price stability and technical collaboration.

In addition to direct cost impacts, tariffs reshape strategic decisions around localization and capacity siting. Facing persistent tariff risk, some organizations accelerate nearshoring or onshoring initiatives to reduce exposure to cross-border duties and to shorten supply chains. This movement influences capital deployment, as companies weigh the trade-offs between the higher initial capital required for localized facilities and the operational benefits of reduced border friction, shorter lead times, and improved control over quality-critical inputs. Conversely, regions that maintain open trade policies and competitive supplier ecosystems can attract outsourced production and enable multinational companies to centralize specialized manufacturing tasks.

Tariffs also interact with regulatory and logistical dynamics. Increased customs inspections and documentation requirements extend lead times for critical materials, amplifying the need for higher safety stock levels and more granular inventory management. Moreover, the cumulative effect of tariffs on specialized consumables and single-use components can accelerate investment in alternative technologies such as reusable bioreactors or local fabrication of ancillary equipment, where feasible. In sum, the 2025 tariff environment compels a more strategic orientation toward supplier diversification, resilience planning, and the re-evaluation of global footprint strategies for biomanufacturing stakeholders.

Key segmentation insights revealing how nuanced product types, enabling technologies, discrete process stages, varied end users, operational scales, cell line selections, and process modes determine capability investments and commercialization strategies

A nuanced segmentation framework clarifies where capability investments and strategic emphasis will be most consequential across product types, technologies, process stages, end users, operational scales, cell lines, and process modes. When looking across product types, cell and gene therapies demand unique manufacturing paradigms that include CAR-T therapies, cell therapies, and gene editing therapies with high sensitivity to small-batch, patient-specific production logistics, whereas enzymes span diagnostic and industrial use cases that prioritize throughput and cost efficiency. Monoclonal antibodies fragment into autoimmune, infectious disease, and oncology applications with divergent potency and purity needs. Recombinant proteins, including cytokines, growth factors, and hormones, typically require tightly controlled upstream and downstream workflows. Vaccines encompass a spectrum of platforms-live attenuated, mRNA, subunit, and viral vector vaccines-each of which imposes distinct cold-chain and fill-finish constraints.

Technological segmentation further underscores differences in capital allocation and operational design. Cell-free systems, whether sold as expression kits or integrated synthesis platforms, introduce options for decentralized manufacturing and rapid prototyping. Continuous bioprocessing elements-such as continuous chromatography, inline monitoring systems, and perfusion technologies-enable steady-state operations that reduce batch-to-batch variability. Modular facilities built from prefabricated modules or skid-mounted systems deliver faster commissioning, while single-use systems comprised of single-use bags, bioreactors, and tubing reduce cleaning validation burdens and cross-contamination risk. Process stage segmentation clarifies where value is created: upstream processing activities like bioreactor operation, cell culture, and media preparation set biological performance, while downstream processing through chromatography, filtration, and purification, together with formulation activities such as fill-and-finish, lyophilization, and packaging, determine final product stability and patient readiness.

End-user segmentation differentiates academic and research institutions, biotech companies, contract manufacturing organizations, and pharmaceutical companies as distinct decision-makers with varied priorities. Operation scale separates clinical, pilot, and commercial stages, each with its own tolerance for risk and capital intensity. Cell line choice-CHO cell variants like CHO-DG44 and CHO-K1, E. coli strains such as BL21 and K12, and yeast species including Pichia pastoris and Saccharomyces cerevisiae-influences expression yield, glycosylation profiles, and downstream purification strategies. Finally, process mode selection among batch, continuous, fed-batch, and perfusion determines facility layout, analytics needs, and staffing models. Integrating these segmentation lenses helps executives prioritize investments that align with modality-specific technical constraints and commercial trajectories.

Regional dynamics and strategic implications across the Americas, Europe Middle East and Africa, and Asia-Pacific that influence capacity siting, regulatory harmonization, talent migration, and cross-border collaboration for biomanufacturing leaders

Regional dynamics are central to strategic decision-making as companies decide where to locate capacity, how to structure supply chains, and which regulatory pathways to prioritize. In the Americas, the combination of advanced clinical ecosystems, robust investor interest, and a dense supplier network supports rapid commercialization and the growth of niche manufacturing for personalized therapies; however, supply-chain friction and policy uncertainty can still drive selective nearshoring and stronger vendor qualification efforts. In Europe, Middle East & Africa, regulatory harmonization efforts and strong public-private collaborations are creating attractive hubs for large-volume biologics and vaccine manufacturing, although localized regulatory nuances require region-specific dossier strategies and extended timelines for market entry.

Asia-Pacific presents a bifurcated landscape where mature markets sustain high-quality contract manufacturing capacity and emerging markets accelerate investments in local production to ensure sovereign supply for essential biologics and vaccines. Across all regions, cross-border collaboration remains essential, as technology providers, contract manufacturers, and developers form transnational partnerships to optimize cost, access specialist skills, and achieve scale. Talent flows, regulatory convergence, and infrastructure investments-such as logistics corridors and cold-chain networks-will therefore determine which regions become centers of excellence for particular modalities. Importantly, companies that align their footprint strategy with local incentives, skilled labor pools, and supply ecosystems will be better positioned to manage regulatory complexity and reduce time-to-clinic across the Americas, Europe, Middle East & Africa, and Asia-Pacific.

Company-level insights highlighting how pharmaceutical developers, contract manufacturers, technology providers, and system integrators are reshaping portfolios, forming strategic alliances, and optimizing manufacturing footprints to capture opportunity

Leading companies across the biomanufacturing value chain are responding to the evolving landscape by pursuing a mix of capability expansion, strategic partnerships, and targeted technology adoption. Contract manufacturing organizations are increasingly offering integrated services that span cell banking, analytical development, and commercial-scale fill-finish in order to capture greater value and reduce client time to market. Technology providers are focusing on modularization, single-use content, and digital platforms that enable remote monitoring and predictive maintenance, thereby lowering operational risk and supporting multi-site orchestration. Pharmaceutical developers are differentiating by retaining strategic control over critical steps-such as cell line development and process characterization-while outsourcing routine scale-up and high-volume production to specialized partners.

Across the ecosystem, strategic alliances and co-investment models are proliferating as a way to share development risk and accelerate access to capacity. Companies are also prioritizing investments in advanced analytics and automation to reduce batch variability, improve yield, and accelerate regulatory approvals. Talent strategies have become a point of competitive differentiation, with firms investing in cross-disciplinary training programs to bridge gaps between process development, data science, and quality assurance. Finally, corporate governance around supply resilience is evolving: executive teams now require scenario planning for tariff shocks, supplier disruptions, and rapid demand surges, and they increasingly expect portfolio managers to demonstrate supply continuity plans as part of go/no-go commercialization decisions.

Actionable strategic recommendations for industry leaders to accelerate adoption of advanced bioprocessing, secure resilient supply networks, align commercial models with regulatory evolutions, and prioritize scalable investments for long-term advantage

Industry leaders should take pragmatic, prioritized actions to secure advantage amid rapid technological and policy change. First, accelerate deployment of modular and single-use assets for early-stage and flexible commercial production to reduce time-to-deploy and lower validation overhead. This approach allows organizations to pilot innovative process modes such as perfusion or continuous chromatography within a constrained capital envelope, and then scale selectively as product economics justify larger fixed investments. Second, enhance supplier diversification and strategic sourcing agreements to mitigate tariff-related cost inflections and minimize the risk of single-source failures; in parallel, develop contingency plans that include local fabrication partners and validated secondary suppliers.

Third, invest in digital quality and process analytics to support real-time release strategies and to satisfy evolving regulatory expectations. Such capabilities shorten approval timelines and enable more efficient tech transfer across sites. Fourth, cultivate workforce resilience through structured cross-training programs that integrate process science, automation skills, and data literacy, ensuring teams can operate highly automated, multi-site networks. Fifth, adopt a selective nearshoring framework that evaluates total landed cost, regulatory alignment, and lead-time reduction benefits versus capital outlay. Finally, pursue collaborative models with academic centers and technology providers to stay at the leading edge of modalities such as cell-free systems and mRNA platforms; by doing so, leaders can capture first-mover advantages while distributing technical risk.

Transparent research methodology detailing integrated primary and secondary research, expert interviews, data triangulation, validation processes, segmentation mapping, and reproducible assessment techniques for robust market insight generation

The research methodology underpinning this analysis draws on an integrated approach that combines primary interviews, secondary literature synthesis, and rigorous triangulation to ensure robustness and reproducibility. Primary research included structured interviews with senior executives across development, manufacturing, procurement, and regulatory functions, alongside in-depth conversations with technology vendors, system integrators, and contract manufacturers. These engagements surfaced practical constraints, investment priorities, and real-world examples of technology transfer and scaling challenges. Secondary research encompassed peer-reviewed literature, public regulatory guidance documents, and technical white papers to contextualize trends and to validate technical assertions.

Data triangulation was applied to reconcile insights across sources: qualitative interview data were cross-referenced with technical specifications, procurement practices, and regulatory guidance to identify convergent themes. Segmentation logic was iteratively validated with subject-matter experts to ensure that product types, technology classes, process stages, end-user categories, operation scales, cell lines, and process modes reflect industry realities and purchasing behaviors. Finally, the methodology incorporated scenario analysis to explore how tariff shocks, supply disruptions, and rapid adoption of new process technologies could affect strategic choices. Where applicable, methodological limitations and areas for further research are documented to guide readers in interpreting the findings and applying them within their own organizational contexts.

A concise strategic conclusion synthesizing critical takeaways, risk-mitigation imperatives, investment priorities, and forward-looking considerations for stakeholders seeking to lead in next-generation biomanufacturing

In conclusion, next-generation biomanufacturing represents a strategic inflection point where technological innovation, supply-chain strategy, and regulatory adaptation converge to reshape industry economics and competitive dynamics. The maturation of continuous bioprocessing, modular facilities, single-use systems, and digital analytics creates a pathway for faster, more reliable production of complex biologics, but realizing these benefits requires intentional investment in capabilities and partnerships. Leaders must therefore align capital allocation with modality-specific needs, prioritize supplier resilience in the face of geopolitical and tariff-induced disruptions, and build cross-functional teams capable of managing automated, data-rich operations.

Looking ahead, the organizations that will succeed are those that adopt a systems view-integrating process development, regulatory strategy, and commercial planning-and that remain agile in their footprint decisions. The imperative is not only to adopt new technologies but to embed them within governance frameworks that ensure quality, reproducibility, and rapid scale-up. By combining targeted investments in flexible infrastructure, strategic supplier relationships, and workforce development, stakeholders can navigate uncertainty and capture the transformative potential of next-generation biomanufacturing.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Next-Generation Biomanufacturing Market, by Product Type

  • 8.1. Cell And Gene Therapies
    • 8.1.1. Car-T Therapies
    • 8.1.2. Cell Therapies
    • 8.1.3. Gene Editing Therapies
  • 8.2. Enzymes
    • 8.2.1. Diagnostic Enzymes
    • 8.2.2. Industrial Enzymes
  • 8.3. Monoclonal Antibodies
    • 8.3.1. Autoimmune
    • 8.3.2. Infectious Diseases
    • 8.3.3. Oncology
  • 8.4. Recombinant Proteins
    • 8.4.1. Cytokines
    • 8.4.2. Growth Factors
    • 8.4.3. Hormones
  • 8.5. Vaccines
    • 8.5.1. Live Attenuated Vaccines
    • 8.5.2. Mrna Vaccines
    • 8.5.3. Subunit Vaccines
    • 8.5.4. Viral Vector Vaccines

9. Next-Generation Biomanufacturing Market, by Technology

  • 9.1. Cell-Free Systems
    • 9.1.1. Cell-Free Expression Kits
    • 9.1.2. Cell-Free Synthesis Platforms
  • 9.2. Continuous Bioprocessing
    • 9.2.1. Continuous Chromatography
    • 9.2.2. Inline Monitoring Systems
    • 9.2.3. Perfusion Systems
  • 9.3. Modular Facilities
    • 9.3.1. Prefabricated Modules
    • 9.3.2. Skid-Mounted Systems
  • 9.4. Single-Use Systems
    • 9.4.1. Single-Use Bags
    • 9.4.2. Single-Use Bioreactors
    • 9.4.3. Single-Use Tubing And Connectors

10. Next-Generation Biomanufacturing Market, by Process Stage

  • 10.1. Downstream Processing
    • 10.1.1. Chromatography
    • 10.1.2. Filtration
    • 10.1.3. Purification
  • 10.2. Formulation
    • 10.2.1. Fill And Finish
    • 10.2.2. Lyophilization
    • 10.2.3. Packaging
  • 10.3. Upstream Processing
    • 10.3.1. Bioreactor Operation
    • 10.3.2. Cell Culture
    • 10.3.3. Media Preparation

11. Next-Generation Biomanufacturing Market, by Operation Scale

  • 11.1. Clinical Scale
  • 11.2. Commercial Scale
  • 11.3. Pilot Scale

12. Next-Generation Biomanufacturing Market, by Cell Line

  • 12.1. Cho Cell
    • 12.1.1. Cho-DG44
    • 12.1.2. Cho-K1
  • 12.2. E. Coli
    • 12.2.1. Bl21
    • 12.2.2. K12
  • 12.3. Yeast
    • 12.3.1. Pichia Pastoris
    • 12.3.2. Saccharomyces Cerevisiae

13. Next-Generation Biomanufacturing Market, by Process Mode

  • 13.1. Batch
  • 13.2. Continuous
  • 13.3. Fed Batch
  • 13.4. Perfusion

14. Next-Generation Biomanufacturing Market, by End User

  • 14.1. Academic And Research Institutions
  • 14.2. Biotech Companies
  • 14.3. Contract Manufacturing Organizations
  • 14.4. Pharmaceutical Companies

15. Next-Generation Biomanufacturing Market, by Region

  • 15.1. Americas
    • 15.1.1. North America
    • 15.1.2. Latin America
  • 15.2. Europe, Middle East & Africa
    • 15.2.1. Europe
    • 15.2.2. Middle East
    • 15.2.3. Africa
  • 15.3. Asia-Pacific

16. Next-Generation Biomanufacturing Market, by Group

  • 16.1. ASEAN
  • 16.2. GCC
  • 16.3. European Union
  • 16.4. BRICS
  • 16.5. G7
  • 16.6. NATO

17. Next-Generation Biomanufacturing Market, by Country

  • 17.1. United States
  • 17.2. Canada
  • 17.3. Mexico
  • 17.4. Brazil
  • 17.5. United Kingdom
  • 17.6. Germany
  • 17.7. France
  • 17.8. Russia
  • 17.9. Italy
  • 17.10. Spain
  • 17.11. China
  • 17.12. India
  • 17.13. Japan
  • 17.14. Australia
  • 17.15. South Korea

18. United States Next-Generation Biomanufacturing Market

19. China Next-Generation Biomanufacturing Market

20. Competitive Landscape

  • 20.1. Market Concentration Analysis, 2025
    • 20.1.1. Concentration Ratio (CR)
    • 20.1.2. Herfindahl Hirschman Index (HHI)
  • 20.2. Recent Developments & Impact Analysis, 2025
  • 20.3. Product Portfolio Analysis, 2025
  • 20.4. Benchmarking Analysis, 2025
  • 20.5. Agilent Technologies, Inc.
  • 20.6. Amyris, Inc.
  • 20.7. Applikon Biotechnology BV
  • 20.8. bbi-biotech GmbH
  • 20.9. Biofluidica, Inc.
  • 20.10. Codexis, Inc.
  • 20.11. Danaher Corporation
  • 20.12. Eppendorf AG
  • 20.13. ESCO Group
  • 20.14. Eurofins Scientific SE
  • 20.15. Evolva Holding SA
  • 20.16. Evonik Industries AG
  • 20.17. GEA Group AG
  • 20.18. GENEWIZ, Inc. by Azenta Life Sciences
  • 20.19. Genomatica, Inc.
  • 20.20. Ginkgo Bioworks Holdings, Inc.
  • 20.21. Hamilton Company
  • 20.22. Illumina, Inc.
  • 20.23. Koninklijke DSM N.V.
  • 20.24. LanzaTech, Inc.
  • 20.25. Macrogen Inc.
  • 20.26. Merck KGaA
  • 20.27. Novozymes A/S
  • 20.28. Oxford Nanopore Technologies plc
  • 20.29. PBS Biotech, Inc.
  • 20.30. PerkinElmer Inc.
  • 20.31. QIAGEN N.V.
  • 20.32. Sartorius AG
  • 20.33. Shanghai Bailun Biotechnology Co., Ltd.
  • 20.34. Solaris Biotechnology Srl by DONALDSON ITALIA S.R.L.
  • 20.35. Takara Bio Inc.
  • 20.36. Thermo Fisher Scientific Inc.
  • 20.37. ZETA GmbH
  • 20.38. Zymergen Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY PROCESS STAGE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY OPERATION SCALE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CELL LINE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY PROCESS MODE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. UNITED STATES NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 15. CHINA NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CELL AND GENE THERAPIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CELL AND GENE THERAPIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CELL AND GENE THERAPIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CELL AND GENE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CAR-T THERAPIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CAR-T THERAPIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CAR-T THERAPIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CELL THERAPIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CELL THERAPIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CELL THERAPIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY GENE EDITING THERAPIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY GENE EDITING THERAPIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY GENE EDITING THERAPIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY ENZYMES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY ENZYMES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY ENZYMES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY ENZYMES, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY DIAGNOSTIC ENZYMES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY DIAGNOSTIC ENZYMES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY DIAGNOSTIC ENZYMES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY INDUSTRIAL ENZYMES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY INDUSTRIAL ENZYMES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY INDUSTRIAL ENZYMES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY AUTOIMMUNE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY AUTOIMMUNE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY AUTOIMMUNE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY RECOMBINANT PROTEINS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY RECOMBINANT PROTEINS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY RECOMBINANT PROTEINS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CYTOKINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CYTOKINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CYTOKINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY GROWTH FACTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY GROWTH FACTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY GROWTH FACTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY HORMONES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY HORMONES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY HORMONES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY LIVE ATTENUATED VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY LIVE ATTENUATED VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY LIVE ATTENUATED VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY MRNA VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY MRNA VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY MRNA VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY SUBUNIT VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY SUBUNIT VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY SUBUNIT VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY VIRAL VECTOR VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY VIRAL VECTOR VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY VIRAL VECTOR VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CELL-FREE SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CELL-FREE SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CELL-FREE SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CELL-FREE SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CELL-FREE EXPRESSION KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CELL-FREE EXPRESSION KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CELL-FREE EXPRESSION KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CELL-FREE SYNTHESIS PLATFORMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CELL-FREE SYNTHESIS PLATFORMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CELL-FREE SYNTHESIS PLATFORMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CONTINUOUS BIOPROCESSING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CONTINUOUS BIOPROCESSING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CONTINUOUS BIOPROCESSING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CONTINUOUS BIOPROCESSING, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CONTINUOUS CHROMATOGRAPHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CONTINUOUS CHROMATOGRAPHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CONTINUOUS CHROMATOGRAPHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY INLINE MONITORING SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY INLINE MONITORING SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY INLINE MONITORING SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY PERFUSION SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY PERFUSION SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY PERFUSION SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY MODULAR FACILITIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY MODULAR FACILITIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY MODULAR FACILITIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY MODULAR FACILITIES, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY PREFABRICATED MODULES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY PREFABRICATED MODULES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY PREFABRICATED MODULES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY SKID-MOUNTED SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY SKID-MOUNTED SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY SKID-MOUNTED SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY SINGLE-USE SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY SINGLE-USE SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY SINGLE-USE SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY SINGLE-USE SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY SINGLE-USE BAGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY SINGLE-USE BAGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY SINGLE-USE BAGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY SINGLE-USE BIOREACTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY SINGLE-USE BIOREACTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY SINGLE-USE BIOREACTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY SINGLE-USE TUBING AND CONNECTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY SINGLE-USE TUBING AND CONNECTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY SINGLE-USE TUBING AND CONNECTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY PROCESS STAGE, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CHROMATOGRAPHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CHROMATOGRAPHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CHROMATOGRAPHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY FILTRATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY FILTRATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY FILTRATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY PURIFICATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY PURIFICATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY PURIFICATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY FORMULATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY FORMULATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY FORMULATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY FILL AND FINISH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY FILL AND FINISH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY FILL AND FINISH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY LYOPHILIZATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY LYOPHILIZATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY LYOPHILIZATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY PACKAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY PACKAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY PACKAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY BIOREACTOR OPERATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY BIOREACTOR OPERATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY BIOREACTOR OPERATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CELL CULTURE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CELL CULTURE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CELL CULTURE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY MEDIA PREPARATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY MEDIA PREPARATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY MEDIA PREPARATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY OPERATION SCALE, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CLINICAL SCALE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 157. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CLINICAL SCALE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CLINICAL SCALE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 159. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY COMMERCIAL SCALE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 160. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY COMMERCIAL SCALE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY COMMERCIAL SCALE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 162. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY PILOT SCALE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 163. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY PILOT SCALE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 164. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY PILOT SCALE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 165. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CELL LINE, 2018-2032 (USD MILLION)
  • TABLE 166. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CHO CELL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 167. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CHO CELL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 168. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CHO CELL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 169. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CHO CELL, 2018-2032 (USD MILLION)
  • TABLE 170. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CHO-DG44, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 171. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CHO-DG44, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 172. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CHO-DG44, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 173. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CHO-K1, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 174. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CHO-K1, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 175. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CHO-K1, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 176. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY E. COLI, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 177. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY E. COLI, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 178. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY E. COLI, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 179. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY E. COLI, 2018-2032 (USD MILLION)
  • TABLE 180. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY BL21, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 181. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY BL21, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 182. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY BL21, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 183. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY K12, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 184. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY K12, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 185. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY K12, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 186. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY YEAST, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 187. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY YEAST, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 188. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY YEAST, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 189. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY YEAST, 2018-2032 (USD MILLION)
  • TABLE 190. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY PICHIA PASTORIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 191. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY PICHIA PASTORIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 192. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY PICHIA PASTORIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 193. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY SACCHAROMYCES CEREVISIAE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 194. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY SACCHAROMYCES CEREVISIAE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 195. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY SACCHAROMYCES CEREVISIAE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 196. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY PROCESS MODE, 2018-2032 (USD MILLION)
  • TABLE 197. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY BATCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 198. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY BATCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 199. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY BATCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 200. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CONTINUOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 201. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CONTINUOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 202. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CONTINUOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 203. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY FED BATCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 204. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY FED BATCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 205. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY FED BATCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 206. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY PERFUSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 207. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY PERFUSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 208. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY PERFUSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 209. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 210. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 211. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 212. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 213. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY BIOTECH COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 214. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY BIOTECH COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 215. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY BIOTECH COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 216. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CONTRACT MANUFACTURING ORGANIZATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 217. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CONTRACT MANUFACTURING ORGANIZATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 218. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CONTRACT MANUFACTURING ORGANIZATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 219. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 220. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 221. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 222. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 223. AMERICAS NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 224. AMERICAS NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 225. AMERICAS NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CELL AND GENE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 226. AMERICAS NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY ENZYMES, 2018-2032 (USD MILLION)
  • TABLE 227. AMERICAS NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 228. AMERICAS NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2032 (USD MILLION)
  • TABLE 229. AMERICAS NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 230. AMERICAS NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 231. AMERICAS NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CELL-FREE SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 232. AMERICAS NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CONTINUOUS BIOPROCESSING, 2018-2032 (USD MILLION)
  • TABLE 233. AMERICAS NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY MODULAR FACILITIES, 2018-2032 (USD MILLION)
  • TABLE 234. AMERICAS NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY SINGLE-USE SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 235. AMERICAS NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY PROCESS STAGE, 2018-2032 (USD MILLION)
  • TABLE 236. AMERICAS NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 237. AMERICAS NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 238. AMERICAS NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 239. AMERICAS NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY OPERATION SCALE, 2018-2032 (USD MILLION)
  • TABLE 240. AMERICAS NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CELL LINE, 2018-2032 (USD MILLION)
  • TABLE 241. AMERICAS NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CHO CELL, 2018-2032 (USD MILLION)
  • TABLE 242. AMERICAS NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY E. COLI, 2018-2032 (USD MILLION)
  • TABLE 243. AMERICAS NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY YEAST, 2018-2032 (USD MILLION)
  • TABLE 244. AMERICAS NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY PROCESS MODE, 2018-2032 (USD MILLION)
  • TABLE 245. AMERICAS NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 246. NORTH AMERICA NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 247. NORTH AMERICA NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 248. NORTH AMERICA NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CELL AND GENE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 249. NORTH AMERICA NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY ENZYMES, 2018-2032 (USD MILLION)
  • TABLE 250. NORTH AMERICA NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 251. NORTH AMERICA NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2032 (USD MILLION)
  • TABLE 252. NORTH AMERICA NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 253. NORTH AMERICA NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 254. NORTH AMERICA NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CELL-FREE SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 255. NORTH AMERICA NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CONTINUOUS BIOPROCESSING, 2018-2032 (USD MILLION)
  • TABLE 256. NORTH AMERICA NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY MODULAR FACILITIES, 2018-2032 (USD MILLION)
  • TABLE 257. NORTH AMERICA NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY SINGLE-USE SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 258. NORTH AMERICA NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY PROCESS STAGE, 2018-2032 (USD MILLION)
  • TABLE 259. NORTH AMERICA NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 260. NORTH AMERICA NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 261. NORTH AMERICA NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 262. NORTH AMERICA NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY OPERATION SCALE, 2018-2032 (USD MILLION)
  • TABLE 263. NORTH AMERICA NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CELL LINE, 2018-2032 (USD MILLION)
  • TABLE 264. NORTH AMERICA NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CHO CELL, 2018-2032 (USD MILLION)
  • TABLE 265. NORTH AMERICA NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY E. COLI, 2018-2032 (USD MILLION)
  • TABLE 266. NORTH AMERICA NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY YEAST, 2018-2032 (USD MILLION)
  • TABLE 267. NORTH AMERICA NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY PROCESS MODE, 2018-2032 (USD MILLION)
  • TABLE 268. NORTH AMERICA NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 269. LATIN AMERICA NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 270. LATIN AMERICA NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 271. LATIN AMERICA NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CELL AND GENE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 272. LATIN AMERICA NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY ENZYMES, 2018-2032 (USD MILLION)
  • TABLE 273. LATIN AMERICA NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 274. LATIN AMERICA NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2032 (USD MILLION)
  • TABLE 275. LATIN AMERICA NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 276. LATIN AMERICA NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 277. LATIN AMERICA NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CELL-FREE SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 278. LATIN AMERICA NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CONTINUOUS BIOPROCESSING, 2018-2032 (USD MILLION)
  • TABLE 279. LATIN AMERICA NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY MODULAR FACILITIES, 2018-2032 (USD MILLION)
  • TABLE 280. LATIN AMERICA NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY SINGLE-USE SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 281. LATIN AMERICA NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY PROCE